

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3914174

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
TRANSCEND MEDICAL, INC.		06/08/2016
RECEIVING PARTY DATA		
Name:	NOVARTIS AG	
Street Address:	LICHTSTRASSE 35	
City:	BASEL	
State/Country:	SWITZERLAND	
Postal Code:	4056	
PROPERTY NUMBERS Total: 86		
Property Type	Number	
Application Number:	11615615	
Application Number:	11615642	
Application Number:	12107676	
Application Number:	12905003	
Application Number:	12972176	
Application Number:	12972261	
Application Number:	12972325	
Application Number:	14199737	
Application Number:	10712277	
Application Number:	10579330	
Application Number:	12561680	
Application Number:	12898593	
Application Number:	12970482	
Application Number:	13216086	
Application Number:	14466863	
Application Number:	14706893	
Application Number:	14817600	
Application Number:	11615810	
Application Number:	60824396	
Application Number:	60759835	

PATENT

Property Type	Number
Application Number:	60783632
Application Number:	14804008
Application Number:	11624168
Application Number:	60824552
Application Number:	09511979
Application Number:	11509327
Application Number:	12711201
Application Number:	13897313
Application Number:	14610197
Application Number:	14140322
Application Number:	12492051
Application Number:	61075706
Application Number:	61076121
Application Number:	13365175
Application Number:	12175294
Application Number:	60950315
Application Number:	13721941
Application Number:	14165178
Application Number:	14591587
Application Number:	12753494
Application Number:	61166574
Application Number:	13975086
Application Number:	14809827
Application Number:	12973853
Application Number:	61289948
Application Number:	14260041
Application Number:	61815681
Application Number:	12898630
Application Number:	12970567
Application Number:	13245772
Application Number:	13245802
Application Number:	14071500
Application Number:	12694691
Application Number:	61147988
Application Number:	61222054
Application Number:	61246017
Application Number:	14025145
Application Number:	12846201

Property Type	Number
Application Number:	61229660
Application Number:	61353139
Application Number:	13898303
Application Number:	13157221
Application Number:	61353147
Application Number:	14042546
Application Number:	13157180
Application Number:	61353162
Application Number:	14507123
Application Number:	13656326
Application Number:	61550337
Application Number:	61635686
Application Number:	13865927
Application Number:	61635471
Application Number:	14176918
Application Number:	13865947
Application Number:	61637789
Application Number:	14029389
Application Number:	61702179
Application Number:	14078206
Application Number:	61726477
Application Number:	14163364
Application Number:	61757603
Application Number:	14254366
Application Number:	61812606
Application Number:	14283759
Application Number:	61825880
Application Number:	62221918

CORRESPONDENCE DATA

Fax Number: (817)551-4610

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 817-551-8260

Email: patent.docketing@alcon.com

Correspondent Name: ALCON RESEARCH, LTD.

Address Line 1: 6201 SOUTH FREEWAY

Address Line 2: IP LEGAL

Address Line 4: FORT WORTH, TEXAS 76134

ATTORNEY DOCKET NUMBER:	TRANSCEND
NAME OF SUBMITTER:	CANDY SANDERS
SIGNATURE:	/Candy Sanders/
DATE SIGNED:	06/13/2016
Total Attachments: 6 source=2016-06-09_ASN_Transcend to NAG_Executed__#page1.tif source=2016-06-09_ASN_Transcend to NAG_Executed__#page2.tif source=2016-06-09_ASN_Transcend to NAG_Executed__#page3.tif source=2016-06-09_ASN_Transcend to NAG_Executed__#page4.tif source=2016-06-09_ASN_Transcend to NAG_Executed__#page5.tif source=2016-06-09_ASN_Transcend to NAG_Executed__#page6.tif	

ASSIGNMENT

This Assignment Agreement is entered into by and between Transcend Medical, Inc., 127 Independence Drive, Menlo Park, California 94025, a Delaware corporation, and NOVARTIS AG, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Transcend Medical, Inc. (the "ASSIGNOR") does hereby sell, assign and transfer to NOVARTIS AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest in and to

(1) the patents and patent applications listed in Schedule 1;

(2) all rights to claim priority from any of the patents and patent applications referred to in paragraph (1), or from any application from which any of the patents and applications referred to in paragraphs (1) and (2) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(3) all divisionals of any patent application(s) described in paragraph (1);

(4) all rights and remedies associated with all patents and applications referred to herein, and all patents, utility models, or other grants that issue from any of the applications referred to herein, including the right to sue for and recover past damages and to recover under any law permitting remedies for infringement prior to issuance of the patent;

(5) all extensions of said patents and supplementary protection certificates based upon said patents and applications for extensions and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, supplementary protection certificates and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this sale, assignment and transfer had not been made.

ASSIGNOR hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing applications, patents, utility models, extensions and supplementary protection certificates, and applications within the scope of (5), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (4) and all applications within the scope of (5), and (iii) make all

PATENT

REEL: 038967 FRAME: 0491

rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE .

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated above.

Executed this 8th day of June, 2016.

TRANSCEND MEDICAL, INC.

BY 
MATTHEW SNAKENBERG

Executed this 9th day of June, 2016.

NOVARTIS AG

BY 
CANDY SANDERS

BY 
BARBARA MCKENZIE

SCHEDULE 1

Country	Filing Number	Filing Date	Novartis Ref. No.
Australia	2004288609	12 November 2004	PAT057300-AU-PCT
Australia	2006202860	04 July 2006	PAT057300-AU-PCTD
Europe	04797015.7	12 November 2004	PAT057300-EP-EPT
United States	11/615,615	22 December 2006	PAT057300-US-CNT
United States	11/615,642	22 December 2006	PAT057300-US-CNT02
United States	12/107,676	22 April 2008	PAT057300-US-CNT03
United States	12/905,003	14 October 2010	PAT057300-US-CNT04
United States	12/972,176	17 December 2010	PAT057300-US-CNT05
United States	12/972,261	17 December 2010	PAT057300-US-CNT06
United States	12/972,325	17 December 2010	PAT057300-US-CNT07
United States	14/199,737	06 March 2014	PAT057300-US-CNT08
United States	10/712,277	14 November 2003	PAT057300-US-NP
United States	10/579,330	12 November 2004	PAT057300-US-PCT
Australia	2006336598	22 December 2006	PAT057301-AU-PCT
Australia	2014200171	10 January 2014	PAT057301-AU-PCTD
Belgium	12180924.8	28 November 2012	PAT057301-BE-ETD
Canada	2637656	22 December 2006	PAT057301-CA-PCT
Switzerland	06848140.7	22 December 2006	PAT057301-CH-EPT
Switzerland	12180924.8	28 November 2012	PAT057301-CH-ETD
China	200680051236.1	22 December 2006	PAT057301-CN-PCT
China	201310135379.2	18 April 2013	PAT057301-CN-PCTD
Germany	06848140.7	22 December 2006	PAT057301-DE-EPT
Germany	12180924.8	28 November 2012	PAT057301-DE-ETD
Europe	06848140.7	22 December 2006	PAT057301-EP-EPT
Europe	12180924.8	28 November 2012	PAT057301-EP-ETD
Europe	15179434.4	31 July 2015	PAT057301-EP-ETD02
Spain	12180924.8	28 November 2012	PAT057301-ES-ETD
France	06848140.7	22 December 2006	PAT057301-FR-EPT
France	12180924.8	28 November 2012	PAT057301-FR-ETD
United Kingdom	06848140.7	22 December 2006	PAT057301-GB-EPT
United Kingdom	12180924.8	28 November 2012	PAT057301-GB-ETD
Italy	12180924.8	28 November 2012	PAT057301-IT-ETD
Japan	2012-068718	26 March 2012	PAT057301-JP-PCTD
Netherlands	12180924.8	28 November 2012	PAT057301-NL-ETD
Poland	12180924.8	28 November 2012	PAT057301-PL-ETD

Portugal	12180924.8	28 November 2012	PAT057301-PT-ETD
Sweden	12180924.8	28 November 2012	PAT057301-SE-ETD
Turkey	12180924.8	28 November 2012	PAT057301-TR-ETD
United States	12/561,680	17 September 2009	PAT057301-US-CNT
United States	12/898,593	05 October 2010	PAT057301-US-CNT02
United States	12/970,482	16 December 2010	PAT057301-US-CNT03
United States	13/216,086	23 August 2011	PAT057301-US-CNT04
United States	14/466,863	22 August 2014	PAT057301-US-CNT05
United States	14/706,893	07 May 2015	PAT057301-US-CNT06
United States	14/817,600	04 August 2015	PAT057301-US-CNT07
United States	11/615,810	22 December 2006	PAT057301-US-NP
United States	60/824,396	01 September 2006	PAT057301-US-PSP
United States	60/759,835	17 January 2006	PAT057301-US-PSP02
United States	60/783,632	17 March 2006	PAT057301-US-PSP03
Canada	2637602	17 January 2007	PAT057302-CA-PCT
Europe	07718113.9	17 January 2007	PAT057302-EP-EPT
Japan	2008-551364	17 January 2007	PAT057302-JP-PCT
United States	14/804,008	20 July 2015	PAT057302-US-CNT
United States	11/624,168	17 January 2007	PAT057302-US-NP
United States	60/824,552	05 September 2006	PAT057302-US-PSP
United States	09/511,979	24 February 2000	PAT057304-US-NP
United States	11/509,327	23 August 2006	PAT057305-US-CNT
United States	12/711,201	23 February 2010	PAT057305-US-CNT02
United States	13/897,313	17 May 2013	PAT057305-US-CNT03
United States	14/610,197	30 January 2015	PAT057305-US-CNT04
Europe	09771056.0	25 June 2009	PAT057309-EP-EPT
United States	14/140,322	24 December 2013	PAT057309-US-CNT
United States	12/492,051	25 June 2009	PAT057309-US-NP
United States	61/075,706	25 June 2008	PAT057309-US-PSP
United States	61/076,121	26 June 2008	PAT057309-US-PSP02
Japan	2010-517166	17 July 2008	PAT057310-JP-PCT
United States	13/365,175	02 February 2012	PAT057310-US-CNT
United States	12/175,294	17 July 2008	PAT057310-US-NP
United States	60/950,315	17 July 2007	PAT057310-US-PSP
United States	13/721,941	20 December 2012	PAT057311-US-CNT
United States	14/165,178	27 January 2014	PAT057311-US-

			CNT02
United States	14/591,587	07 January 2015	PAT057311-US-CNT03
United States	12/753,494	02 April 2010	PAT057311-US-NP
United States	61/166,574	03 April 2009	PAT057311-US-PSP
United States	13/975,086	23 August 2013	PAT057313-US-CNT
United States	14/809,827	12 August 2015	PAT057313-US-CNT02
United States	12/973,853	20 December 2010	PAT057313-US-NP
United States	61/289,948	23 December 2009	PAT057313-US-PSP
United States	14/260,041	23 April 2014	PAT057314-US-NP
United States	61/815,681	24 April 2013	PAT057314-US-PSP
Europe	10704246.7	27 January 2010	PAT057315-EP-EPT
Europe	12188742.6	16 October 2012	PAT057315-EP-EPT02
Japan	2011-548248	27 January 2010	PAT057315-JP-PCT
United States	12/898,630	05 October 2010	PAT057315-US-CNT
United States	12/970,567	16 December 2010	PAT057315-US-CNT02
United States	13/245,772	26 September 2011	PAT057315-US-CNT03
United States	13/245,802	26 September 2011	PAT057315-US-CNT04
United States	14/071,500	04 November 2013	PAT057315-US-CNT05
United States	12/694,691	27 January 2010	PAT057315-US-NP
United States	61/147,988	28 January 2009	PAT057315-US-PSP
United States	61/222,054	30 June 2009	PAT057315-US-PSP02
United States	61/246,017	25 September 2009	PAT057315-US-PSP03
United States	14/025,145	12 September 2013	PAT057316-US-CNT
United States	12/846,201	29 July 2010	PAT057316-US-NP
United States	61/229,660	29 July 2009	PAT057316-US-PSP
United States	61/353,139	09 June 2010	PAT057316-US-PSP02
United States	13/898,303	20 May 2013	PAT057317-US-CNT
United States	13/157,221	09 June 2011	PAT057317-US-NP
United States	61/353,147	09 June 2010	PAT057317-US-PSP
United States	14/042,546	30 September 2013	PAT057318-US-CNT
United States	13/157,180	09 June 2011	PAT057318-US-NP
United States	61/353,162	09 June 2010	PAT057318-US-PSP
Europe	12841249.1	19 October 2012	PAT057319-EP-EPT
United States	14/507,123	06 October 2014	PAT057319-US-CNT
United States	13/656,326	19 October 2012	PAT057319-US-NP
United States	61/550,337	21 October 2011	PAT057319-US-PSP
United States	61/635,686	19 April 2012	PAT057319-US-PSP02
United States	13/865,927	18 April 2013	PAT057320-US-NP
United States	61/635,471	19 April 2012	PAT057320-US-PSP

Australia	2013249153	18 April 2013	PAT057321-AU-PCT
Canada	2870549	18 April 2013	PAT057321-CA-PCT
China	201380031978.8	18 April 2013	PAT057321-CN-PCT
Eurasia	201590502	18 April 2013	PAT057321-EA-EAT
Europe	13778653.9	18 April 2013	PAT057321-EP-EPT
Japan	2015-507194	18 April 2013	PAT057321-JP-PCT
Russia	2014145853	18 April 2013	PAT057321-RU-PCT
United States	14/176,918	10 February 2014	PAT057321-US-CNT
United States	13/865,947	18 April 2013	PAT057321-US-NP
United States	61/637,789	24 April 2012	PAT057321-US-PSP
Eurasia	201590968	17 September 2013	PAT057322-EA-EAT
Europe	13836841.0	17 September 2013	PAT057322-EP-EPT
United States	14/029,389	17 September 2013	PAT057322-US-NP
United States	61/702,179	17 September 2012	PAT057322-US-PSP
Russia	2015113823	17 September 2013	PAT057322-RU-PCT
United States	14/078,206	12 November 2013	PAT057323-US-NP
United States	61/726,477	14 November 2012	PAT057323-US-PSP
United States	14/163,364	24 January 2014	PAT057324-US-NP
United States	61/757,603	28 January 2013	PAT057324-US-PSP
United States	14/254,366	16 April 2014	PAT057325-US-NP
United States	61/812,606	16 April 2013	PAT057325-US-PSP
Europe	14801761.9	21 May 2014	PAT057326-EP-EPT
United States	14/283,759	21 May 2014	PAT057326-US-NP
United States	61/825,880	21 May 2013	PAT057326-US-PSP
United States	62/221,918	22 September 2015	PAT057327-US-PSP